Book
← All deal pages
Deal page · Announced January 15, 2026

Boston Scientific agreed to buy Penumbra. What the months before close decide for the people who built it.

A cash and stock deal valued at $374 a share at announcement, about $14.5 billion in enterprise value. Stockholders elect cash or Boston Scientific stock, and proration can change the mix they receive. Equity awards follow their own terms, with no election. In quarterly reports dated October 29 and November 2, 2026, Penumbra and Boston Scientific said the deal was expected to close in early 2027. If you hold Penumbra RSUs, PSUs, options or ESPP shares, the decisions are already in front of you. This page is the public record, the timeline, and the questions to ask before close.

Facts checked November 16, 2026.

Mateo DellovoFounded BFA Wealth Management in 2015

Fiduciary adviser. Advisory fees only. Check my record

The deal, from the public record
  • Announced January 15, 2026 by Boston Scientific and Penumbra. The merger agreement is dated January 14, 2026, and the board of each company approved it.
  • Each Penumbra share can be exchanged, at the holder’s election, for $374.00 in cash or 3.8721 Boston Scientific shares, subject to proration (Section 2.01). The announcement valued the 3.8721 shares at $374 using Boston Scientific’s volume weighted average price over the 10 trading days as of January 13, 2026, and put the enterprise value at approximately $14.5 billion. The proxy statement says the exchange ratio is fixed and “will not be adjusted for stock price changes.”
  • Proration sets the overall mix. Cash goes to 73.26% of the Penumbra shares converted in the merger and stock to 26.74% (Section 2.02(a)). If cash elections exceed 73.26%, shares with no election get stock and every cash election is cut back by the same fraction, with the rest paid in stock. If cash elections fall short, shares with no election move to cash first, then stock elections, pro rata (Section 2.02(b)).
  • The election form is mailed at least 20 business days before the expected election deadline, to holders of record as of five business days before the mailing date, and you can elect cash for some shares and stock for others (Section 2.03(a) and (c)). Shares without a properly completed election form received by the deadline count as shares with no election (Section 2.03(d)).
  • The election deadline is 5 p.m. New York City time on the date five business days before Boston Scientific’s good faith estimate of the closing date, unless the companies agree on another time and date. Penumbra and Boston Scientific will announce the deadline by press release at least five business days before it. If the closing date is delayed, the deadline is delayed too, and the companies will promptly announce the delay and, once set, the new deadline (Section 2.03(d)).
  • You can change or revoke an election by written notice the exchange agent receives before the deadline (Section 2.03(e)). The proxy statement says you “will not be able to transfer” the shares covered by your election unless you revoke it before the deadline.
  • Penumbra stockholders approved the merger at a special meeting on May 6, 2026, with 28,564,786 shares voting for, 85,334 against and 15,813 abstaining.
  • The conditions left after the vote include the end of the Hart-Scott-Rodino waiting period and the other government approvals listed in a schedule to the agreement (Section 7.01(c)). The companies filed under the HSR Act on February 13, 2026, and each received a request for additional information, known as a Second Request, from the FTC on March 16, 2026. The proxy statement said the merger was expected to be subject to clearance or approval under the competition laws of the European Union and the competition and foreign investment laws of certain other countries.
  • At announcement the companies said the transaction was expected to be completed in 2026. Penumbra’s Form 10-Q dated October 29, 2026 said the merger was expected to close in early 2027. Boston Scientific’s Form 10-Q dated November 2, 2026 said the companies were responding to the Second Request and the transaction was expected to be completed in early 2027, subject to closing conditions including regulatory clearances.
  • If the merger has not taken effect by January 14, 2027, the agreement can generally be terminated. Either company may extend that date by written notice in three month steps, up to January 14, 2028, if on the scheduled end date the regulatory conditions are still unmet and the other conditions have been met or waived, or could be met if closing took place that day (Section 8.01(b)). Closing takes place on the fifth business day after the last condition is met or waived, unless the companies agree in writing on another date (Section 1.02).
  • Options, vested or unvested, with an exercise price below the equity award value are cancelled at close for $274.00 in cash plus 1.0353 Boston Scientific shares for each share, with the exercise price and tax withholding taken from the cash first and then from the shares. Options at or above that value are cancelled with no payment (Section 2.06(a) and (b)). The equity award value is $274.00 plus 1.0353 times the average of Boston Scientific’s daily volume weighted average prices on the NYSE over the 10 consecutive trading days ending two trading days before the closing date (Section 9.03).
  • Every RSU still outstanding at close that was granted before January 1, 2026 vests at close. So do RSUs granted for a performance period that ended before that date (other than sales incentive plan awards), RSUs vested but not yet settled, RSUs that vest in full at closing under their own terms, and RSUs held by directors who are not employees or by specified officers. Each is paid $274.00 in cash plus 1.0353 Boston Scientific shares per share, with tax withholding taken from the cash first (Section 2.06(c)).
  • Cash and shares for options and for the RSUs that vest at close are due as promptly as practicable after close and no later than 30 calendar days after it (Section 2.06(a) and (c)). For those RSUs, where paying on that schedule would cause a Section 409A penalty tax, payment comes on the earliest date that avoids it (Section 2.06(c)).
  • Other RSUs, including PSUs and sales incentive plan awards that are not on that list, become Boston Scientific RSUs. Performance conditions for periods not complete at close are reasonably assessed on actual performance through the time the merger takes effect. Each converted RSU covers your Penumbra RSU shares times 1.0353, plus your Penumbra RSU shares times $274.00 divided by that 10 trading day Boston Scientific average price, each rounded down. It keeps the vesting terms set out in Penumbra’s disclosure schedule to the agreement, which was not filed, the other terms of the award agreement, and any terms that take effect at closing under the award’s own terms (Section 2.06(d) and Section 9.03).
  • The proxy statement said the ESPP would be frozen and suspended at the end of the offering period in progress as of January 15, 2026, with no new participants and no changes to elections or contributions. The ESPP ends just before the merger takes effect (Section 2.06(e)). Penumbra’s Form 10-K for 2025 says each offering begins on May 20 or November 20 and ends on the following November 19 or May 19.
  • In the merger agreement, Boston Scientific agreed with Penumbra that for one year after close it would provide continuing employees base pay no less favorable than before close, incentive opportunities no less favorable in the aggregate than those it provides to its similarly situated employees (through December 31, 2027 if that comes first), and benefits, including severance but not any employee stock purchase plan, substantially comparable in the aggregate to Penumbra’s before close or Boston Scientific’s for similarly situated employees (Section 6.05(a)). Section 6.05(d) says nothing in the agreement is intended to create third party beneficiary rights for any employee, which generally means employees can’t enforce these terms themselves. It also says nothing in the agreement creates any right to continued employment or service.
  • In an employee Q&A filed with the SEC on January 15, 2026, Penumbra said unvested RSUs “will generally vest upon the acquisition closing” and be exchanged for a mix of cash and Boston Scientific stock, and that employees with equity awards would get more details closer to close. The merger agreement’s list in Section 2.06(c) sets out which RSUs vest at close, and RSUs not on that list become Boston Scientific RSUs instead (Section 2.06(d)).

Sources. Boston Scientific and Penumbra joint press release, January 15, 2026, Boston Scientific’s Form 8-K and the merger agreement dated January 14, 2026, filed as Exhibit 2.1, Penumbra’s employee Q&A filed with the SEC on January 15, 2026, the proxy statement/prospectus dated April 1, 2026, Penumbra’s Form 8-K on the May 6, 2026 vote, Penumbra’s Form 10-K for 2025, and the Forms 10-Q for the quarter ended September 30, 2026 of Penumbra and Boston Scientific. BFA Wealth Management isn’t affiliated with Boston Scientific or Penumbra. The terms and dates above come from the announcement and filings named here, as of the date the facts were checked. They can change before close, so confirm the treatment of your own awards with HR before you act.

What a cash or stock election means for Penumbra employees

Each Penumbra share you own at close becomes $374.00 in cash or 3.8721 Boston Scientific shares, by your election, but proration means you may not get the mix you elect. Cash goes to 73.26% of shares overall. In the proxy statement’s example, if 80% of shares elect cash, a holder who elects cash for 1,000 shares receives cash for 915.75 of them and stock for the rest. The 3.8721 ratio is fixed, so the value of the stock part rises and falls with Boston Scientific’s share price until close. Once you elect on shares, you can’t transfer them unless you revoke the election before the deadline, and you can’t revoke it after the deadline.

Your equity awards are paid on their own terms, without an election. Options and the RSUs that vest at close are paid in a set mix, $274.00 in cash plus 1.0353 Boston Scientific shares per share, with any exercise price and tax withholding taken from the cash first. The value of the 1.0353 shares moves with Boston Scientific’s share price. The cash and shares paid for RSUs are taxed as pay. Federal withholding on that pay can be a flat 22%, with 37% required on supplemental pay above $1 million in a year, and that may be less than you owe.

If an RSU was granted on or after January 1, 2026 and is not on the list that vests at close, you generally end up holding a Boston Scientific RSU. Its vesting terms are set out in a schedule to the agreement that was not filed, so ask HR for them in writing. Each one is generally taxed as pay when it settles. So this deal calls for both guides, Before Your Company Is Sold for Cash for what is paid at close and Before Your Company Is Sold for Stock for the Boston Scientific shares and RSUs you keep.

The proxy statement says a U.S. holder’s receipt of cash and Boston Scientific shares for Penumbra shares “will be a taxable transaction for U.S. federal income tax purposes,” and that gain or loss generally will be long term capital gain or loss for shares held more than one year. It also says its discussion does not address all aspects that may matter to holders subject to special rules, such as a holder who acquired shares through compensatory options or stock purchase plans or otherwise as compensation. Shares from a Section 423 ESPP have their own holding periods, more than two years from the grant date and more than one year from purchase. Unless both have passed, a sale or cash out is generally a disqualifying disposition, with part of the value taxed as ordinary income. Part of the gain can be ordinary income even when both have passed.

The twelve questions to ask before close
  1. Which of my options and RSUs pay out at close, which convert, and will HR confirm that in writing?
  2. For RSUs that convert, what vesting terms apply after close under the schedule to the merger agreement, and how many Boston Scientific RSUs will each grant become?
  3. For my PSUs, which vest at close, which convert, and how will performance count for periods still open at close?
  4. Where are my Penumbra shares held, at a broker, in a stock plan account or with the transfer agent, will I get an election form for each, and does any broker set an earlier deadline?
  5. What mix of cash and stock fits my plan, and how could proration change the mix I elect?
  6. Should I sell Penumbra shares I own in an open trading window before I elect, or elect on all of them, and how does each choice change the tax year and whether my gain is long term?
  7. If I hold ESPP shares, is the plan a Section 423 plan, and will my shares have met its holding periods, more than two years from the grant date and more than one year from purchase, by close?
  8. If I am let go after close, what severance applies, and does my offer letter, a severance plan or my award agreement speed up vesting of the RSUs that convert?
  9. Could the golden parachute rules (Section 280G) reach me as an officer, a more than 1% owner or one of the highest paid 1% of employees, and would my deal payments reach three times my base amount, where a 20% excise tax can apply?
  10. What will withholding look like on the cash and shares paid for my RSUs at close, and on each converted RSU as it vests, and is a flat 22% federal rate, or 37% on supplemental pay above $1 million in a year, enough?
  11. When can I sell Boston Scientific shares after close, and how much of my net worth should one stock be?
  12. What happens to my awards and my election if the deal does not close, and what would I do then?

Nobody at your company is paid to answer these for you. HR will tell you the mechanics. Your CPA will handle the return. The person who puts it all on one page, in the order it matters, is usually missing. That is the gap we fill.

The timeline

The months before close

Ask HR, in writing, which of your awards vest at close and which convert, and how your PSUs will be counted. Gather your grant agreements, PSU terms, ESPP purchase records and any severance terms. List every account that holds Penumbra shares. Decide on any share sale with a tax projection, not a guess.

The election window

The election form is mailed at least 20 business days before the expected deadline, and a press release announces the deadline at least five business days ahead. The deadline moves if close is delayed. Shares you elect on can’t be transferred unless you revoke before the deadline. Know what cash you will need for taxes, and when.

Close

Each Penumbra share you own becomes $374.00 in cash or 3.8721 Boston Scientific shares, by your election and after proration. Options and the RSUs that vest at close are paid $274.00 in cash plus 1.0353 Boston Scientific shares per share, less withholding and any exercise price, generally within 30 calendar days after close. Other RSUs become Boston Scientific RSUs. Keep every statement and confirmation for your tax return.

30 to 90 days after close

A plan for the cash, with the tax bill set aside first. A plan for the Boston Scientific shares you receive and the RSUs still vesting, inside Boston Scientific’s trading rules. A tax projection for this year and next. The job decision, if there is one.

The checklist. The twelve questions on one page, to bring to HR, your CPA, or your kitchen table. Leave your email and it is yours, along with the letters, two most weeks, unsubscribe any time.

Privacy Policy

Where BFA fits

We do this for tech and biotech people paid in stock. It starts with a free fifteen minute Checkup, then the Full Picture, a free hour on your whole situation, then the Plan. No commissions on investment products, advisory fees only.

Fifteen minutes, a straight answer either way. Nothing to prepare. If you know roughly what you hold and what HR has told you so far, that’s plenty.

Book a 15-minute Checkup

Not ready to book? Answer four quick questions, and you’ll see the first thing to check for your situation right away. I’ll also email you what to check next.

This page is general education from public filings, not advice for your situation. Neither BFA Wealth Management, LLC nor Mateo Dellovo has a business relationship with Boston Scientific or Penumbra or any nonpublic information about them. Terms can change before close.

This page covers events through the close of the deal. It is not updated after that.